Dan O'Day, Gilead CEO (Kevin Dietsch/UPI/Bloomberg via Getty Images)
Gilead doles out $280M upfront to regain Trodelvy rights in China, other regional territories
A little over two months after Trodelvy earned its first approval in China, Gilead is making moves to regain the drug’s rights in the country …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
